TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03055416

Intervention type: OTHER
Group type: OTHER
Intervention: Mobile Men App Prototype
Description: Testing of app functionality
Study: NCT02008734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD0332991
Study: NCT01960803

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Electron Radiotherapy
Description: Intraoperative Electron Radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure.
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 4 m
Description: Oral alprazolam 4 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 4 m
Description: Oral alprazolam 4 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 4 m
Description: Oral alprazolam 4 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 4 m
Description: Oral alprazolam 4 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg qualifying session
Description: Qualifying session (2 mg oral alprazolam)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg qualifying session
Description: Qualifying session (2 mg oral alprazolam)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg qualifying session
Description: Qualifying session (2 mg oral alprazolam)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg qualifying session
Description: Qualifying session (2 mg oral alprazolam)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg qualifying session
Description: Qualifying session (2 mg oral alprazolam)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg qualifying session
Description: Qualifying session (2 mg oral alprazolam)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg qualifying session
Description: Qualifying session (2 mg oral alprazolam)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg qualifying session
Description: Qualifying session (2 mg oral alprazolam)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg qualifying session
Description: Qualifying session (2 mg oral alprazolam)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg qualifying session
Description: Qualifying session (2 mg oral alprazolam)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg qualifying session
Description: Qualifying session (2 mg oral alprazolam)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg qualifying session
Description: Qualifying session (2 mg oral alprazolam)
Study: NCT04590768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermotein based meals
Description: various meal products: bread, soup and an occasional burgers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Matching control meals with whey protein and wheat bran
Description: various meal products: bread, soup and an occasional burgers
Study: NCT02618382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1300mg tranexamic acid by mouth once before surgery and then three times a day for up to three days or until they are discharged from the hospital, whichever comes first
Study: NCT02084927

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HBOT
Description: HBOT of 2 ATA for 90 minutes, for 60 treatments

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBOT
Description: HBOT of 2 ATA for 90 minutes, for 60 treatments
Study: NCT04489303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Response App
Description: Participants will receive the Caring Response mobile app containing the Virtual Patient Behavioral Response Training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Educational/Resources Program
Description: Participants will receive a traditional educational/resources program, containing a workbook and online resources.
Study: NCT02966496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acri.LISA366D multifocal aspheric IOLs
Description: The implantation of Acri.LISA366D multifocal aspheric IOLs are used in the test group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TecnisZ9001 multifocal aspheric IOLs
Description: The implantation of TecnisZ9001 multifocal aspheric IOLs are used in the test group.
Study: NCT01010789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: flexible dose 150-250mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 150-250mg/day; flexible dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Placebo comparator
Study: NCT02621463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilator (V60, Philips)
Description: The clinician will determine the concentration of oxygen that shall be delivered to the patient. The ventilator is capable of providing concentrations between 21% - 100% of oxygen. Unless otherwise directed by the clinician, the default setting of 40% will be used.
Study: NCT01363011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF
Description: E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg qualifying session
Description: Qualifying session (2 mg oral alprazolam)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg qualifying session
Description: Qualifying session (2 mg oral alprazolam)
Study: NCT01363011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COBI
Description: COBI 150 mg tablet administered with food orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: ATV 300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: DRV 800 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTI
Description: Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.
Study: NCT03715686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wire localization
Description: Pathologically proven positive axillary lymph node will be clip-marked before the initiation of neoadjuvant chemotherapy. After the completion of neoadjuvant chemotherapy, a wire will be placed to localize the clip-marked node before surgery. During surgery, a standard sentinel lymph node biopsy will be performed as well as the removal of the wire localized node. ALND will be performed in all participants.
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo qualifying session
Description: Qualifying control session (oral placebo)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo qualifying session
Description: Qualifying control session (oral placebo)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo qualifying session
Description: Qualifying control session (oral placebo)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo qualifying session
Description: Qualifying control session (oral placebo)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo qualifying session
Description: Qualifying control session (oral placebo)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo qualifying session
Description: Qualifying control session (oral placebo)
Study: NCT04159181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Oral solution lactulose (20g lactulose/200mL water).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Oral solution lactulose (20g lactulose/200mL water).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Picoprep
Description: Cathartic to accomplish an evacuation of the colonic content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (water)
Description: oral administration of Water (200mL).
Study: NCT01205893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neovasc Reducer
Description: Implantation of the Reducer

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Control - No device implanted
Study: NCT01021631

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: Red blood cell (RBC) transfusion will be given when hematocrit fall below 30% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 30% or higher, no additional transfusion is necessary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: Red blood cell (RBC) transfusion will be only given when hematocrit fall below 24% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 24% or higher, no additional transfusion is necessary.
Study: NCT04571333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mi2000 Totally Implantable Cochlear Implant
Description: During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
Study: NCT01645111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clevidipine
Study: NCT01662362

Intervention type: DEVICE
Group type: OTHER
Intervention: Testing Donor Specimens with ESA Chagas
Description: Donors will be asked to return for a follow-up blood draw.
Study: NCT02807779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone infusion
Description: Participants will receive dexamethasone infusion following plain balloon angioplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug coated balloon
Description: Participants will receive angioplasty with a drug-coated balloon following plain balloon angioplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain balloon angioplasty
Description: Participants will receive plain balloon angioplasty only
Study: NCT02618226

Intervention type: DEVICE
Intervention: Optic nerve ultrasound
Description: Measurement of ONSD with concomitant invasive ICP measurement will be performed at enrollment and at least daily for a total of 7 days. Additional measurements of ONSD may be performed at any time following any decline in Glasgow Coma Scale (GCS) score by 2+ points during the 7 day period.
Study: NCT01140737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily. A four week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.
Study: NCT00116493

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron-folic acid and mebendazole
Description: 100 mg iron for pregnant women, 25 mg iron for children~1 mg of folic acid for pregnant women, 100 ug folic acid for children 500 mg of mebendazole for both pregnant women and children

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: 100 mg twice a day for 3 days; Iron-folic acid also given

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamins
Description: Iron-folic acid also given; Includes vitamins A, C, B12, E, and B2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole + Multivitamin
Description: Multivitamins + Mebendazole at 100 mg twice a day for 3 days; Iron-folic acid also given
Study: NCT01134627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Participants who are self-administering Rebif® (IFN beta-1a) 44 microgram (mcg) as subcutaneous (sc) injection thrice weekly will also receive minocycline 100 milligram (mg) tablet twice daily as an add-on therapy in accordance with clinical practice for 96 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who are self-administering Rebif® (IFN beta-1a) 44 mcg as sc injection thrice weekly will also receive placebo tablets twice daily for 96 weeks.
Study: NCT00610753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Behavior Therapy
Description: This treatment is usually delivered in two phases: In the first phase there is an initial investigation of family behavior around feeding using a family meal followed by family therapy focused on enhancing feeding of the anorexic child in order to promote weight gain. In the second phase, once weight gain is well established the adolescent is given greater autonomy over feeding and in later sessions over other issues.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Systems Family Therapy
Description: This therapy is applied in three phases. 1. In the first 2 or 3-sessions the treatment is explained to the family and an initial examination of family issues begins. 2. In the second phase family interactions and psychological processes are explored with clarification for family members. 3. In the third phase knowledge of family patterns is refined aiming for behavior change.
Study: NCT04276987

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs-derived exosomes
Description: 5 times aerosol inhalation of MSCs-derived exosomes (2.0\*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).
Study: NCT02165605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HylaCare
Description: cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02414906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Description: Goal-directed therapy with fluids and dobutamine
Study: NCT04365855

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic Resonance Elastography
Description: Combines MRI imaging with sound waves to create a visual map (elastogram) showing the stiffness of body tissues.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: Clinical blood tests with a focus on liver function parameters and diabetes
Study: NCT01711047

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency catheter Ablation
Description: In this arm, catheter ablation would be performed in the left atrium and would include pulmonary vein isolation and linear ablations (roof and mitral isthmus lines)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency catheter ablation
Description: In this arm, catheter ablation would be performed in the left atrium, including pulmonary vein isolation, linear ablations (roof and mitral isthmus lines) and Complex Fractionated Atrial Electrograms (CFAE) ablation.
Study: NCT02085356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protect your family
Description: Protect Your Family intervention is a manualized, closed, structured behavioral risk reduction program targeting HIV, stigma, disclosure, communication, intimate partner violence (IPV), PMTCT knowledge, safer conception, family planning and dual method sexual barrier use.~Intervention participants will attend 3 prenatal weekly 2 hour gender-specific (male or female, 5-7 participants) group sessions followed by 1 individual counseling session and 2 monthly couples or individual (women-only) counseling sessions (1 prenatal, 2 postpartum) led by study-trained clinic staff (e.g., nurses, HIV counseling and testing (HCT) counselors) plus standard of care (PMTCT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protect your family
Description: Protect Your Family intervention is a manualized, closed, structured behavioral risk reduction program targeting HIV, stigma, disclosure, communication, intimate partner violence (IPV), PMTCT knowledge, safer conception, family planning and dual method sexual barrier use.~Intervention participants will attend 3 prenatal weekly 2 hour gender-specific (male or female, 5-7 participants) group sessions followed by 1 individual counseling session and 2 monthly couples or individual (women-only) counseling sessions (1 prenatal, 2 postpartum) led by study-trained clinic staff (e.g., nurses, HIV counseling and testing (HCT) counselors) plus standard of care (PMTCT)
Study: NCT00914823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kisspeptin 112-121
Description: One or more IV or SC doses of kisspeptin 112-121, and/or short infusion (up to 12 hours) of kisspeptin 112-121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: One or more IV doses of GnRH, and/or SC administration of GnRH
Study: NCT03018119

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Study: NCT03680391

Intervention type: PROCEDURE
Intervention: Cesarean section
Description: Both groups cesarean section will be held with the same technique:~* spinal anethesia~* pfennenstiel imcision~* lower segment cesarean section~* suturing uterus in two layers while exterionezed~* gentle manibulation~* no towels in gutters will be used

Intervention type: PROCEDURE
Intervention: Cesarean section
Description: Both groups cesarean section will be held with the same technique:~* spinal anethesia~* pfennenstiel imcision~* lower segment cesarean section~* suturing uterus in two layers while exterionezed~* gentle manibulation~* no towels in gutters will be used
Study: NCT04166682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Description: cardiac rehabilitation done at home

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Description: Routine care and followup
Study: NCT04365855

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver biopsy
Description: If indicated per MRE results a biopsy will be taken of the liver.
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo qualifying session
Description: Qualifying control session (oral placebo)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo qualifying session
Description: Qualifying control session (oral placebo)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo qualifying session
Description: Qualifying control session (oral placebo)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo qualifying session
Description: Qualifying control session (oral placebo)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo qualifying session
Description: Qualifying control session (oral placebo)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo qualifying session
Description: Qualifying control session (oral placebo)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo qualifying session
Description: Qualifying control session (oral placebo)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo qualifying session
Description: Qualifying control session (oral placebo)
Study: NCT02462304

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: End-Point-Management grid laser

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT02899793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy
Study: NCT01168713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin once daily for 5 days:~Levofloxacin 750 mg PO Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEM-101
Description: CEM-101 once daily for 5 days:~CEM-101 800 mg PO Day 1~CEM-101 400 mg PO Days 2-5
Study: NCT01119274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing algorithm
Description: Loading and monitoring dose according to genotype-guided dosing algorithm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-genotype-guided dosing algorithm
Description: Loading and monitoring dose according to non-genotype-guided dosing algorithm
Study: NCT01428063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir
Study: NCT04365855

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fibro Scan
Description: If indicated per MRE results a fibroscan will be performed of the liver.
Study: NCT01661283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: 10 mg tablet once daily
Study: NCT02639546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.
Study: NCT02968004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: Once weekly subcutaneous injection using pre-filled pen device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Once daily subcutaneous injection of Genotropin using pre-filled pen device.